Fortis Healthcare's Turnaround Under IHH

Fortis Healthcare (FORH) is showing significant operational improvement following its transition into a professionally managed hospital platform under IHH Healthcare. The strategic overhaul since IHH's promoter ownership change in FY19 has focused on strengthening governance, addressing balance sheet issues, and divesting non-core assets. These foundational changes are projected to drive substantial financial growth, with estimated FY26E sales of ₹9,000 crore, EBITDA of ₹2,050 crore, and Profit After Tax (PAT) of ₹1,080 crore. This marks a considerable recovery from its FY18 performance, underpinning a positive outlook.

Valuation Peaks Amidst Peer Comparison

Despite the clear operational turnaround, Fortis Healthcare's valuation is a key point of discussion. The company currently trades at high Price-to-Earnings (P/E) multiples, estimated around 61.8x to 72.89x on a Trailing Twelve Month (TTM) basis, and approximately 51x for the next fiscal year. Analysts value its hospital business at 30x 12-month forward EV/EBITDA and its diagnostics arm at 23x, aligning with peer valuations. Competitors like Apollo Hospitals Enterprise and Max Healthcare Institute also command premium multiples, with P/E ratios around 61.39x-72.41x for Apollo and 67.0x-69.05x for Max Healthcare. Max Healthcare maintains a debt-to-equity ratio of 32.6%, while Apollo Hospitals has a substantial market capitalization of approximately ₹1.11 trillion. Fortis Healthcare's own market capitalization stands at around $7.01 billion USD, or ₹69,966 crore. The Indian healthcare sector benefits from increased spending and initiatives like Ayushman Bharat, contributing to these high valuations. Fortis's stock performance shows a 11.4% decline over the six months leading up to April 23, 2026, contrasted with a 38.65% increase over the past year.

Lingering Governance Concerns

Fortis Healthcare's journey has been marked by significant historical governance challenges. In FY18, the company reported sales of ₹45 billion (₹4,500 crore), EBITDA of ₹2 billion (₹200 crore), and a net loss of ₹1.5 billion (₹150 crore). The period prior to IHH's acquisition was characterized by a stressed balance sheet and governance issues, including investigations into potentially fraudulent related-party transactions. Regulatory bodies like SEBI and SFIO scrutinized these activities, which involved inter-corporate deposits with promoter-controlled entities. These past governance failures and investigations led auditors to qualify financial statements on multiple counts, significantly impacting investor trust and historical stock performance. While IHH Healthcare has worked to professionalize management and strengthen governance, the shadow of these past issues can attract increased scrutiny and affect investor confidence.

Analyst Outlook and Future Catalysts

Analysts have initiated coverage on Fortis Healthcare with a 'Buy' rating and a target price of ₹1,100, reflecting confidence in the company's operational turnaround and expansion strategy. Brokerage consensus generally supports a 'Buy' rating, with an average 12-month price target around ₹1,044, suggesting moderate upside potential. However, some caution remains, with MarketsMojo rating the stock 'Sell' as of April 22, 2026, citing an 'expensive' valuation. The successful execution of growth plans and sustained improvement in return ratios will be crucial for Fortis to justify its current market pricing. Key upcoming events include the investor roadshow in Mumbai from April 27-28, 2026, and the Q4 FY26 earnings report expected around May 30, 2026, which will offer further insights into its performance trajectory.